Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 + nab-paclitaxel + PD-1 antibody for initially unresectable intrahepatic cholangiocarcinoma
ChiCTR2200065096Phase 2Not yet recruiting
- Sponsor
- Xiangyang Central Hospital
- Start
- Oct 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur, paclitaxel and PD-1 Monoclonal Antibody in intrahepatic cholangiocarcinoma (ICC), sponsored by Xiangyang Central Hospital. Primary endpoint: Objective response rate. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
tegafurpaclitaxelPD-1 Monoclonal Antibody
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2200065096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065096.